Evidence map›Paper›PMID 35236933›Full record

ArticleBone marrow transplantation2022

Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation.

Tomoki Iemura, Yasuyuki Arai, Toshio Kitawaki, Junya Kanda, Tadakazu Kondo, Yasunori Ueda, Takuto Mori, Kazunori Imada, Akihito Yonezawa, Kazuhiro Yago and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 1 country.

Tomoki IemuraDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasuyuki AraiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ysykrai@kuhp.kyoto-u.ac.jp.ORCID 0000-0002-9662-5093
Toshio KitawakiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6373-3442
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6704-3633
Tadakazu KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-8959-6271
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan.
Takuto MoriDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.ORCID 0000-0002-0945-0513
Akihito YonezawaDepartment of Hematology, Kokura Memorial Hospital, Fukuoka, Japan.
Kazuhiro YagoDepartment of Hematology, Shizuoka General Hospital, Shizuoka, Japan.
Naoyuki AnzaiDepartment of Hematology, Takatsuki Red Cross Hospital, Osaka, Japan.
Shinichi KotaniDepartment of Hematology, Tenri Hospital, Nara, Japan.
Masaharu NohgawaDeparment of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Toshiyuki KitanoDepartment of Hematology, Kitano Hospital, Osaka, Japan.
Mitsuru ItohDepartment of Hematology, Kyoto City Hospital, Kyoto, Japan.
Nobuyoshi ArimaDeparment of Hematology, Shinko Hospital, Hyogo, Japan.
Toshinori MoriguchiDepartment of Hematology, Kyoto-Katsura Hospital, Kyoto, Japan.
Mitsumasa WatanabeDepartment of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Masaaki TsujiDepartment of Hematology, Japan Red Cross Otsu Hospital, Shiga, Japan.
Kouhei YamashitaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-7678-4284
Kyoto Stem Cell Transplantation Group (KSCTG)
Kyoto University · JPHyogo Prefectural Amagasaki General Medical Center · JPJapanese Red Cross Society Wakayama Medical Center · JPKitano Hospital · JPKokura Memorial Hospital · JPKurashiki Central Hospital · JPKyoto City Hospital · JPKyoto Katsura Hospital · JPOsaka Hospital · JPOtsu Red Cross Hospital · JPShinko Hospital · JPShizuoka General Hospital · JPTakatsuki Red Cross Hospital · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infection is one of the lethal adverse events after cord blood transplantation (CBT). Human leukocyte antigen (HLA) and killer immunoglobulin-like receptor (KIR) ligand divergences can increase the risk of viral infection due to conflicting interactions between virus-infected cells and immune cells. However, the relationship between these disparities and the frequency of viral infection after CBT remains to be evaluated. Herein, we have conducted a retrospective multicenter study to assess the effect of HLA and KIR ligand mismatches on viral infections after CBT. The study included 429 patients, among which 126 viral infections occurred before day 100. Viral infection was significantly associated with poorer overall survival (OS; hazard ratio [HR] 1.74, p < 0.01). Patients harboring ≥3 mismatches in the HLA allele and inhibitory KIR ligand mismatches (HLA & KIR mismatches) had a significantly greater prevalence of viral infection (HR 1.66, p = 0.04). Thus, patients with HLA & KIR mismatches had poorer outcomes in terms of non-relapse mortality (HR 1.61, p = 0.05). Our study demonstrates the unfavorable impacts of HLA & KIR mismatches on viral infections and non-relapse mortality after CBT. Evaluating the viral infection risk and performance of an appropriate and early intervention in high-risk patients and optimizing the graft selection algorithm could improve the outcome of CBTs.

Indexed as

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationVirus DiseasesHistocompatibility Antigens Class IHLA AntigensHumansLigandsReceptors, KIRRisk FactorsHistocompatibility Antigens Class IHLA AntigensLigandsReceptors, KIR

Identifiers

PMID35236933
OpenAlexW4214920182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.